Nuvectis reports Q2 2026 results as ciprocopan wins first China approval
Nuvectis says partner Haisco's China approval of ciprocopan for untreated PNH patients validates the drug as it plans a U.S. IND submission in the fourth quarter.
SEC filing
Latest
2 stories